RNA design company Wayfinder Biosciences announced that it raised a $3.5M series seed round led by Notation Capital and Divergent Capital to continue its groundbreaking work in the use of RNA as a detection and therapeutic platform.
Wayfinder Biosciences Raises $3.5M to Program RNA
Share: